Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients.

Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T.

Ann Neurol. 2020 Feb 13. doi: 10.1002/ana.25701. [Epub ahead of print]

PMID:
32056253
2.

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T.

JAMA Neurol. 2019 Oct 7. doi: 10.1001/jamaneurol.2019.3365. [Epub ahead of print]

PMID:
31589278
3.

Environmental and genetic risk factors for MS: an integrated review.

Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, Langer-Gould A.

Ann Clin Transl Neurol. 2019 Sep;6(9):1905-1922. doi: 10.1002/acn3.50862. Epub 2019 Aug 7. Review.

4.

Pregnancy and Family Planning in Multiple Sclerosis.

Langer-Gould AM.

Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi: 10.1212/CON.0000000000000745. Review.

PMID:
31162316
5.

Validation of an algorithm for identifying MS cases in administrative health claims datasets.

Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, Kaye WE, Wagner L, Tremlett H, Chen LH, Leung S, Evans C, Yao S, LaRocca NG; United States Multiple Sclerosis Prevalence Workgroup (MSPWG).

Neurology. 2019 Mar 5;92(10):e1016-e1028. doi: 10.1212/WNL.0000000000007043. Epub 2019 Feb 15.

6.

The prevalence of MS in the United States: A population-based estimate using health claims data.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15. Erratum in: Neurology. 2019 Oct 8;93(15):688.

7.

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.

Nelson LM, Wallin MT, Marrie RA, Culpepper WJ, Langer-Gould A, Campbell J, Buka S, Tremlett H, Cutter G, Kaye W, Wagner L, Larocca NG; United States Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):469-480. doi: 10.1212/WNL.0000000000007044. Epub 2019 Feb 15. Review.

8.

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Alping P, Piehl F, Langer-Gould A, Frisell T; COMBAT-MS Study Group.

Epidemiology. 2019 Mar;30(2):230-233. doi: 10.1097/EDE.0000000000000948.

9.

Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry.

Chi C, Shao X, Rhead B, Gonzales E, Smith JB, Xiang AH, Graves J, Waldman A, Lotze T, Schreiner T, Weinstock-Guttman B, Aaen G, Tillema JM, Ness J, Candee M, Krupp L, Gorman M, Benson L, Chitnis T, Mar S, Belman A, Casper TC, Rose J, Moodley M, Rensel M, Rodriguez M, Greenberg B, Kahn L, Rubin J, Schaefer C, Waubant E, Langer-Gould A, Barcellos LF.

PLoS Genet. 2019 Jan 17;15(1):e1007808. doi: 10.1371/journal.pgen.1007808. eCollection 2019 Jan.

10.

Vitamin D deficiency is an etiological factor for MS - No.

Langer-Gould A, Lucas RM.

Mult Scler. 2019 Apr;25(5):639-641. doi: 10.1177/1352458518808469. Epub 2018 Nov 30. No abstract available.

PMID:
30499745
11.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
12.

MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics.

Langer-Gould A, Lucas R, Xiang AH, Chen LH, Wu J, Gonzalez E, Haraszti S, Smith JB, Quach H, Barcellos LF.

Nutrients. 2018 Feb 27;10(3). pii: E268. doi: 10.3390/nu10030268.

13.

Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis.

Langer-Gould A, Lucas RM, Xiang AH, Wu J, Chen LH, Gonzales E, Haraszti S, Smith JB, Quach H, Barcellos LF.

Nutrients. 2018 Feb 7;10(2). pii: E184. doi: 10.3390/nu10020184.

14.

Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.

Langer-Gould A, Wu J, Lucas R, Smith J, Gonzales E, Amezcua L, Haraszti S, Chen LH, Quach H, James JA, Barcellos LF, Xiang AH.

Neurology. 2017 Sep 26;89(13):1330-1337. doi: 10.1212/WNL.0000000000004412. Epub 2017 Aug 30.

15.

Breastfeeding, ovulatory years, and risk of multiple sclerosis.

Langer-Gould A, Smith JB, Hellwig K, Gonzales E, Haraszti S, Koebnick C, Xiang A.

Neurology. 2017 Aug 8;89(6):563-569. doi: 10.1212/WNL.0000000000004207. Epub 2017 Jul 12.

16.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group.

Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847. [Epub ahead of print]

17.

Perceptions of Multiple Sclerosis in Hispanic Americans: Need for Targeted Messaging.

Obiwuru O, Joseph S, Liu L, Palomeque A, Tarlow L, Langer-Gould AM, Amezcua L.

Int J MS Care. 2017 May-Jun;19(3):131-139. doi: 10.7224/1537-2073.2015-081.

18.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

19.

Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility.

Hellwig K, Chen LH, Stancyzk FZ, Langer-Gould AM.

PLoS One. 2016 Mar 7;11(3):e0149094. doi: 10.1371/journal.pone.0149094. eCollection 2016.

20.

Breastfeeding and Disease-Modifying Therapy for Multiple Sclerosis--Reply.

Hellwig K, Langer-Gould AM.

JAMA Neurol. 2016 Apr;73(4):480-1. doi: 10.1001/jamaneurol.2015.4821. No abstract available.

PMID:
26926044

Supplemental Content

Loading ...
Support Center